Development and characterization of a first-in-class adjustable-dose gene therapy system

Area of Science:

• Biotechnology
• Gene Therapy
• Nanomedicine

Background:

• Gene therapy is limited by inability to adjust dosage, high cost, and toxicity.
• Current gene therapy approaches are primarily used for rare diseases.
• A need exists for advanced gene therapy systems with improved control and safety.

Purpose of the Study:

• To develop a first-in-class adjustable-dose gene therapy system.
• To optimize biocompatibility, localization, durability, and cost of gene therapy delivery.
• To create a platform for replacing protein treatments with a single-injection gene therapy.

Main Methods:

• Developed and characterized lipid nanoparticle (LNP) delivery systems.
• Optimized in vitro transfection efficiency and cytocompatibility in human adipocytes.
• Evaluated durability, immunogenicity, and expression adjustment in mice using bioluminescence imaging and qPCR.

Main Results:

• Achieved 81.3% transfection efficiency in human adipocytes with maintained cytocompatibility.
• Demonstrated durable in vivo expression (>6 months) localized to adipose tissue.
• Showcased adjustable gene expression via cryolipolysis, focused ultrasound, and pharmacologically inducible apoptosis.

Conclusions:

• Developed a novel, low-cost, adjustable-dose gene therapy platform.
• The system enables subcutaneous delivery and dose adjustment.
• This platform has the potential to replace conventional protein treatments.